(RLAY) Relay Therapeutics - Ratings and Ratios
Precision, Oncology, Genetics, Inhibitors, Degraders, Treatments
RLAY EPS (Earnings per Share)
RLAY Revenue
Description: RLAY Relay Therapeutics
Relay Therapeutics, Inc. is a clinical-stage precision medicine company revolutionizing the drug discovery process with a focus on targeted oncology and genetic disease indications. The companys innovative approach leverages computational modeling capabilities to analyze protein motion, enabling the development of novel small molecule therapeutics. With a robust pipeline, Relay Therapeutics is advancing multiple product candidates, including RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, and lirafugratinib (RLY-4008), a receptor tyrosine kinase inhibitor, among others.
The companys lead product candidates are being developed for various cancer indications, including breast cancer, solid tumors, and vascular malformations. RLY-2608 is also being explored in combination with other therapies, such as fulvestrant and atirmociclib, through collaborations with major pharmaceutical companies like Pfizer Inc. Additionally, Relay Therapeutics has partnerships with D. E. Shaw Research, LLC, and Elevar Therapeutics, Inc., to further its research and development efforts.
From a technical analysis perspective, RLAYs stock price has been trending upwards, with its 20-day simple moving average (SMA) at $3.26 and 50-day SMA at $3.10, indicating a potential bullish signal. However, the stock is still below its 200-day SMA of $4.42, suggesting that it has room to grow. The average true range (ATR) of 0.22, or 6.72%, indicates moderate volatility. Given the current price of $3.32, we can expect the stock to continue its upward trend, potentially reaching $4.00 in the near term, driven by the companys progress in its clinical trials and partnerships.
Fundamentally, Relay Therapeutics has a market capitalization of $552.05M USD, with a negative P/E ratio due to its current losses. The companys return on equity (RoE) is -44.16, indicating significant investment in research and development. As the company advances its product candidates through clinical trials and potentially achieves regulatory approvals, we can expect its market capitalization to grow. Based on the current pipeline and partnerships, we forecast that RLAYs stock price could reach $6.00 within the next 12-18 months, driven by the potential approval and commercialization of its lead product candidates.
RLAY Stock Overview
| Market Cap in USD | 709m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-07-16 |
RLAY Stock Ratings
| Growth Rating | -85.4% |
| Fundamental | 26.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.0% |
| Analyst Rating | 4.31 of 5 |
RLAY Dividends
Currently no dividends paidRLAY Growth Ratios
| Growth Correlation 3m | 50.9% |
| Growth Correlation 12m | -71.4% |
| Growth Correlation 5y | -97.7% |
| CAGR 5y | -44.87% |
| CAGR/Max DD 3y | -0.49 |
| CAGR/Mean DD 3y | -0.67 |
| Sharpe Ratio 12m | -0.93 |
| Alpha | -68.60 |
| Beta | 0.511 |
| Volatility | 65.22% |
| Current Volume | 1288.3k |
| Average Volume 20d | 1101.9k |
| Stop Loss | 3.7 (-7.3%) |
| Signal | -0.71 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-311.5m TTM) > 0 and > 6% of Revenue (6% = 501.4k TTM) |
| FCFTA -0.34 (>2.0%) and ΔFCFTA 4.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7753 % (prev 1872 %; Δ 5881 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.36 (>3.0%) and CFO -261.4m > Net Income -311.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 20.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.3m) change vs 12m ago 28.94% (target <= -2.0% for YES) |
| Gross Margin 55.68% (prev 84.38%; Δ -28.69pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.11% (prev 4.56%; Δ -3.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -36.34
| (A) 0.89 = (Total Current Assets 680.4m - Total Current Liabilities 32.5m) / Total Assets 728.8m |
| (B) -2.59 = Retained Earnings (Balance) -1.89b / Total Assets 728.8m |
| warn (B) unusual magnitude: -2.59 — check mapping/units |
| (C) -0.36 = EBIT TTM -267.4m / Avg Total Assets 750.7m |
| (D) -29.85 = Book Value of Equity -1.89b / Total Liabilities 63.2m |
| Total Rating: -36.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.80
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -39.93% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.13 = -2.50 |
| 6. ROIC - WACC -43.89% = -12.50 |
| 7. RoE -41.49% = -2.50 |
| 8. Rev. Trend 13.11% = 0.66 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 45.76% = 1.14 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of RLAY shares?
Over the past week, the price has changed by -3.16%, over one month by +19.10%, over three months by +15.65% and over the past year by -47.64%.
Is Relay Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RLAY is around 2.37 USD . This means that RLAY is currently overvalued and has a potential downside of -40.6%.
Is RLAY a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RLAY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.6 | 240.9% |
| Analysts Target Price | 13.6 | 240.9% |
| ValueRay Target Price | 2.6 | -33.8% |
Last update: 2025-09-05 04:58
RLAY Fundamental Data Overview
CCE Cash And Equivalents = 113.9m USD (Cash And Short Term Investments, last quarter)
P/S = 84.8126
P/B = 1.0619
Beta = 1.628
Revenue TTM = 8.36m USD
EBIT TTM = -267.4m USD
EBITDA TTM = -263.5m USD
Long Term Debt = 30.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.52m USD (from shortTermDebt, last quarter)
Debt = 34.2m USD (Calculated: Short Term 3.52m + Long Term 30.7m)
Net Debt = -79.8m USD (from netDebt column, last quarter)
Enterprise Value = 628.9m USD (708.6m + Debt 34.2m - CCE 113.9m)
Interest Coverage Ratio = unknown (Ebit TTM -267.4m / Interest Expense TTM 0.0)
FCF Yield = -39.93% (FCF TTM -251.1m / Enterprise Value 628.9m)
FCF Margin = -3005 % (FCF TTM -251.1m / Revenue TTM 8.36m)
Net Margin = -3728 % (Net Income TTM -311.5m / Revenue TTM 8.36m)
Gross Margin = 55.68% ((Revenue TTM 8.36m - Cost of Revenue TTM 3.70m) / Revenue TTM)
Tobins Q-Ratio = -0.33 (set to none) (Enterprise Value 628.9m / Book Value Of Equity -1.89b)
Interest Expense / Debt = 20.30% (Interest Expense 6.94m / Debt 34.2m)
Taxrate = 21.0% (US default)
NOPAT = -267.4m (EBIT -267.4m, no tax applied on loss)
Current Ratio = 20.92 (Total Current Assets 680.4m / Total Current Liabilities 32.5m)
Debt / Equity = 0.05 (Debt 34.2m / last Quarter total Stockholder Equity 665.7m)
Debt / EBITDA = -0.13 (Net Debt -79.8m / EBITDA -263.5m)
Debt / FCF = -0.14 (Debt 34.2m / FCF TTM -251.1m)
Total Stockholder Equity = 750.8m (last 4 quarters mean)
RoA = -42.75% (Net Income -311.5m, Total Assets 728.8m )
RoE = -41.49% (Net Income TTM -311.5m / Total Stockholder Equity 750.8m)
RoCE = -34.22% (Ebit -267.4m / (Equity 750.8m + L.T.Debt 30.7m))
RoIC = -35.62% (NOPAT -267.4m / Invested Capital 750.8m)
WACC = 8.27% (E(708.6m)/V(742.8m) * Re(7.90%)) + (D(34.2m)/V(742.8m) * Rd(20.30%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 4.03%
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -251.1m)
Revenue Correlation: 13.11 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 44.41
EPS Correlation: 45.76 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 28.89
Additional Sources for RLAY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle